Human Genome Sciences is one of several developers working on a new advance for lupus. This Wall Street Journal piece looks at the pipeline for lupus, which includes programs at Bristol-Myers Squibb [1], Genentech [2] and Biogen Idec [3]. There hasn't been a new therapy approved for lupus in 50 years, but these new drugs--which include Orencia and Rituxan [4]--are being tested as treatments for the disease rather than just the symptoms.
- read the The Wall Street Journal article [5] on lupus
Related Articles:
New warning issued on Rituxan for lupus. Report [6]
HGS adds positive data in extended lupus trial. Report [7]
Links:
[1] http://www.fiercebiotech.com/story/bristol-myers-squibb-shelves-diabetes-drug/2006-05-19
[2] http://www.fiercebiotech.com/story/genentech-hiring-researchers-in-big-rd-push/2007-01-10
[3] http://www.fiercebiotech.com/story/biogen-ucb-ink-200m-development-deal/2006-10-03
[4] http://www.fiercebiotech.com/node/4994
[5] http://online.wsj.com/article/SB116952617634384693.html?mod=health_home_stories
[6] http://www.fiercebiotech.com/story/new-warning-issued-on-rituxan-for-lupus/2006-12-19
[7] http://www.fiercebiotech.com/story/hgs-adds-positive-data-in-extended-lupus-trial/2006-11-14